SYGNIS AG Strengthens Management Team

09-Aug-2016 - Germany

SYGNIS AG announced the appointment of Heikki Lanckriet, PhD, currently Chief Executive Officer (CEO) of Expedeon Holdings Ltd., as co-CEO and Chief Scientific Officer (CSO). The CSO role is a newly created position at SYGNIS. Dr. Lanckriet’s appointment became effective on August 5, 2016. He will also become a member of the Management Board of SYGNIS, along with Pilar de la Huerta, who will serve as co-CEO and Chief Financial Officer (CFO) of the combined organization.

Heikki Lanckriet, PhD, has co-founded Expedeon in 2003.  At Expedeon, he has served as Chief Operating Officer, CSO and CEO, his current position, accumulating a deep knowledge of the life sciences tools and reagents business. Dr. Lanckriet holds a bachelor’s and master’s degree in biochemical engineering from the University of Ghent, Belgium and a PhD in biochemical engineering from the University of Cambridge, UK. He has published papers in peer-reviewed international scientific journals and is named inventor on a number of patents.

“I am very excited to have Heikki join me on the leadership team of SYGNIS,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Heikki’s deep scientific background as well as his knowledge and experience on the operational side  make him an ideal partner. I look forward to working together to lead the new company to future growth and success.”

“I am pleased to have the opportunity to lead the combined organization with Pilar,” said Heikki Lanckriet, PhD.  “We have already worked together both before and during the acquisition and I am convinced that this will be a fruitful and productive collaboration. I look forward to working with the combined teams to achieve faster, sustained growth and create a thriving business.”

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances